@article{e5be746ba9cf48bf83acef9a7e01fc1b,
title = "Choosing the appropriate salvage therapy for B-cell non-Hodgkin lymphoma",
keywords = "B-cell malignancies, Treatment options, non-Hodgkin lymphoma, relapsed disease",
author = "Hamza Hashmi and Mehdi Hamadani and Awan, {Farrukh T.}",
note = "Funding Information: F Awan has received research funding from Pharmacyclics and has served as an advisor for Gilead Sciences, AbbVie, Pharmacyclics, and Janssen Pharmaceuticals. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.",
year = "2018",
month = oct,
day = "13",
doi = "10.1080/14656566.2018.1518430",
language = "English (US)",
volume = "19",
pages = "1631--1634",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "15",
}